Hot Investor Profile: USA-Based VC Firm Seeks to Invest Up to $15M in Life Science Companies With a Strong Focus on Therapeutics Companies

June 27, 2024 ~ Next Phase Admin ~ Leave a comment

A venture capital firm founded in 2019 and headquartered in the US invests in early-stage life science companies, typically in Series A, with a focus on companies with smaller capital requirements. Average check size is $8M USD but can range from $1M-15M USD. The firm typically leads rounds but can also participate in syndicates. Though the firm has not invested in a startup abroad, they are open to global opportunities.

The firm is interested in all sectors of life science, but 80% of their interest is drugs. The remaining 20% is focused on other life science verticals such as devices and diagnostics. Areas of interest include orphaned assets, promising data that could potentially be out-licensed but was overlooked, or nutraceutical products that are being developed into drugs. The firm is indication-agnostic, however, gravitates towards and prefers niche areas such as ophthalmology, rare diseases, dermatology, psychiatry, and cardiometabolic diseases. Ideally, the firm would like to fund proof-of-concept data.

The firm requires to take a board seat. The firm does not have strict company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm Invests in Biotech Companies in Early Clinical Stage of Development, Open to Global Opportunities

June 27, 2024 ~ Next Phase Admin ~ Leave a comment

A venture capital firm that specializes in early-stage in-human clinical biotech ventures are driven by a passion for groundbreaking scientific advancements that have potential to revolutionize healthcare. The firm works closely with global CROs especially those in Australia. Initial check sizes range between $100k-200k USD, which are used directly for the clinical trial, and once Phase 1b starts, the firm will continue to invest at every phase of the trials with check sizes ranging from $100k-1.5M USD. The firm is open to investing in global companies.

The firm invests in biotech companies starting at the in-human clinical trial phase. The firm is indication-agnostic and have worked with companies in CNS, oncology, cardiology, and more.

The firm prefers to take a board advisor seat or have an advisory standpoint as they like to be active investors that provide value. The firm likes to see companies with a robust IP strategy, management teams, and a clear long-term plan from an exit standpoint.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm with USA & China Offices Invests in All Sectors of Life Sciences and Healthcare and Supports Asia Market Entry

June 27, 2024 ~ Next Phase Admin ~ Leave a comment

A venture capital firm founded in 2016 with offices in US and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Innovator’s Pitch Challenge Winners at RESI Europe

June 27, 2024July 5, 2024 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI Europe 2024 in Barcelona last week, 41 innovative companies participated in the highly anticipated Innovator’s Pitch Challenge (IPC). This event provided a unique platform for early-stage life science and healthcare companies to showcase their technologies and attract potential investors.

The IPC finalists had the opportunity to deliver 4-minute pitches to an engaged audience, followed by a 9-minute Q&A session with a panel of expert investor judges. Each participating company also exhibited a poster highlighting their technology in the conference’s exhibit hall.

Many of the pitch companies and the winning companies represented the cutting-edge technology emerging from the Catalonia region, with several being member companies of Biocat, RESI Europe’s co-organizer. Biocat plays a crucial role in driving the growth of Catalonia’s life sciences and health innovation ecosystem.

The competition’s unique voting system allowed registered RESI attendees, including startup executives, early-stage investors, and industry experts, to ‘invest’ in their favorite IPC companies using RESI cash provided at check-in. Attendees based their decisions on the companies’ poster presentations and pitch performances.

Life Science Nation is proud to announce the top three winners of RESI Europe 2024’s Innovator’s Pitch Challenge:

1st Place: Gate2Brain

Jaume Baró, Executive Directorate, Enterprise and Entrepeneurship, Barcelona Activa | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Meritxell Teixidó, PhD, CEO & CSO, Gate2Brain | Robert Fabregat, CEO, Biocat

2nd Place: Ysotope Theranostics

shared image

3rd Place: DyCare

Jaume Baró, Executive Directorate, Enterprise and Entrepeneurship, Barcelona Activa | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Ricardo Jauregui, CTO & Founder, Dycare | Robert Fabregat, CEO, Biocat

Gate2Brain, the first-place winner, will receive complimentary tickets to three RESI events of their choice, a prize valued at $12,000. The second and third-place winners will receive tickets to two and one RESI events, respectively.

For those interested in participating in the next Innovator’s Pitch Challenge, applications are now open for RESI Boston 2024. This event will take place on September 25 at the Westin Copley Place in Boston, featuring a one-day in-person conference followed by two days of virtual partnering. Early application is encouraged as spots are filled on a rolling basis.

Additionally, registration for RESI Boston is now open with super early bird rates available. Prospective attendees can save $500 by registering before Friday, July 5.

The success of RESI Europe 2024 in Barcelona, with its diverse participation and innovative format, underscores the event’s importance in connecting early-stage life science companies with potential investors and industry partners.

Investor Panelists at RESI Europe

June 13, 2024June 13, 2024 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Life Science Nation (LSN) team is gearing up for next week’s highly anticipated RESI Europe conference in Barcelona. With a curated program featuring 9 insightful panels, attendees can expect to gain the latest perspectives on early-stage life science and healthcare investment opportunities.

LSN has assembled diverse panelists representing various investment groups, including seed funds, corporate venture capitalists, early-stage therapeutics, and oncology innovation leaders. These experts will share their strategies, approaches to early-stage investment, perspectives on industry landscapes, insights into startup ecosystems, and much more. As a truly global conference, RESI Europe will also welcome numerous international investors and cross-border investment groups, fostering dynamic discussions and facilitating valuable networking opportunities.

The primary goal of the RESI panels is to facilitate constructive conversations between investors and fundraising CEOs. Attendees can expect to receive tactical advice on effective capital-raising strategies and partnership acquisition, empowering companies to navigate the fundraising journey successfully. These must-attend panels present an unparalleled opportunity for founders and CEOs to engage directly with investors, expand their networks, and gain invaluable insights to propel their businesses forward.

Join the panelists below at RESI Europe:

Speakers

Click Here to See More Investor Speakers

Investor Fireside Chat

June 13, 2024 ~ Next Phase Admin ~ Leave a comment

By Momo Yamamoto, Investor Research Analyst, LSN

This week, Life Science Nation (LSN) hosted our June Investor Fireside Chat which brought together four investors from different parts of the world discussing how early-stage life science investments in the first half of 2024 have looked like so far. We were happy to welcome Farzad Abdi-Dezfuli, Partner from Sarsia, Jenna Aronson, Principal from Two Bear Capital, Tom Gibbs, Investment Director from Debiopharm Group, and Rick Jones, Partner from BioAdvance. The investors gave their thoughts on trends of 2024 and insight to startups looking to fundraise.

Biocat Lunch Keynote at RESI Europe 2024

June 13, 2024 ~ Next Phase Admin ~ Leave a comment

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Biocat will host a lunch keynote session at RESI Europe 2024 on June 17 at the Hotel Hilton Diagonal Mar in Barcelona. The session, titled “Catalonia’s Advanced Therapies Ecosystem: Shaping the Future of ATMPs in Europe,” will take place in the Ballroom, starting at 12 PM. Leading experts will discuss the pivotal role of Catalonia’s advanced therapies ecosystem in driving innovation and clinical advancements in Advanced Therapy Medicinal Products (ATMPs) across Europe. This session, organized by Biocat, will delve into the region’s innovative landscape, highlighting groundbreaking research, investment opportunities, and cutting-edge developments.

The esteemed panel will be moderated by Robert Fabregat, CEO of BIOCAT, and features prominent figures in the field:

Fina Lladós, Vice President General Manager Iberia at Amgen
Silvia Martín-Lluesma, Clinical Senior Manager of Advanced Therapies at Vall d’Hebron Institute of Oncology (VHIO)
Antoni Matilla, Cofounder and Director of Biointaxis
Lluís Pareras, Founder and Managing Partner at Invivo Ventures
Esteve Trias, Executive Medical Director at Leitat Technological Center

Attendees will gain invaluable insights into how Catalonia’s collaborative efforts and strategic initiatives propel Europe to the forefront of advanced therapies. This session is a must-attend for investors, researchers, and industry professionals committed to advancing the field of ATMPs and shaping the future of healthcare. Don’t miss this opportunity to engage with key players and learn about the future of advanced therapies in Europe! If you haven’t registered for RESI Europe yet, you can register now to secure your spot.